The engineered CD8+ T cells demonstrate enhanced cytotoxicity towards an HLA-A*0201+ human β-cell line, suggesting the potential for altering T-cell specificity for mechanistic analysis and downstream therapeutic applications in T1D [36]. This evidence concerns the gene CD8A and type 1 diabetes mellitus.